Management of oral bleedings with recombinant factor VIIa in children with haemophilia A and inhibitor

Haemophilia. 2005 Jan;11(1):2-4. doi: 10.1111/j.1365-2516.2005.01051.x.

Abstract

Dental extraction in patients with haemophilia A and high-titre inhibitor is always a high-risk procedure, which often presents a lot of problems associated with bleeding. Prothrombin complex concentrates or recombinant activated factor VII (rFVIIa) has been used to control bleeding. rFVIIa was administered to five boys with severe haemophilia A complicated with inhibitor, who underwent seven dental extractions. The age of the patients ranged between 8 and 13 years (median 10 years). The concentrate was administered in doses of 90-100 microg kg(-1) body weight. Duration in the therapy and intervals between rFVIIa doses depended on the severity of bleeding. rFVIIa was proven to be highly effective and no side-effects of the product were observed.

Publication types

  • Case Reports
  • Review

MeSH terms

  • Blood Coagulation Factor Inhibitors / analysis
  • Child
  • Factor VII / therapeutic use*
  • Factor VIIa
  • Hemophilia A / blood
  • Hemophilia A / complications*
  • Hemophilia A / drug therapy
  • Hemostasis, Surgical
  • Humans
  • Male
  • Oral Hemorrhage / blood
  • Oral Hemorrhage / drug therapy*
  • Oral Hemorrhage / etiology
  • Recombinant Proteins / therapeutic use*
  • Tooth Extraction / adverse effects

Substances

  • Blood Coagulation Factor Inhibitors
  • Recombinant Proteins
  • Factor VII
  • recombinant FVIIa
  • Factor VIIa